S

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336

Watchlist Manager
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Watchlist
Price: 62.32 CNY -0.73%
Market Cap: 38.4B CNY

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Income from Continuing Operations
¥691.4m
CAGR 3-Years
N/A
CAGR 5-Years
27%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-¥5B
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Income from Continuing Operations
¥1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Income from Continuing Operations
-¥501.1m
CAGR 3-Years
26%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Income from Continuing Operations
¥2.5B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Income from Continuing Operations
-¥266.8m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Glance View

Market Cap
38.5B CNY
Industry
Biotechnology

Sunshine Guojian Pharmaceutical Shanghai Co., Ltd. stands as a beacon of innovation in China’s bustling pharmaceutical landscape. Born from a vision to advance biotech research and development, the company has centered its efforts on the creation of monoclonal antibody drugs. These biologics are pivotal in treating complex diseases such as cancers and autoimmune disorders, positioning Sunshine Guojian at the forefront of biopharmaceutical excellence. The company's prowess is anchored in its robust R&D capabilities, with a specialized team of scientists and cutting-edge facilities driving the creation of therapeutics that meet global standards. By strategically focusing on biologics, the firm not only taps into a growing demand for advanced medical solutions but also strengthens its competitive edge in both domestic and international markets. The economic engine of Sunshine Guojian hums along with a well-oiled strategy of clinical development and commercialization. Partnering with healthcare professionals and institutions, the company ensures that its biologics are effectively integrated into treatment paradigms, thereby enhancing patient care and outcomes. Revenue streams flow through a mix of direct sales and strategic partnerships, both within China and abroad, where collaborative alliances help broaden market reach and drive scale. Moreover, its established networks enable the company to stay attuned to emerging medical needs and regulatory environments, adapting swiftly to maintain its leadership position. This adeptness in maneuvering the complex web of pharmaceutical offerings allows Sunshine Guojian not just to survive but to thrive, fueling sustainable growth and innovation in an ever-evolving health landscape.

Sunshine Guojian Pharmaceutical Shanghai Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
691.4m CNY

Based on the financial report for Dec 31, 2024, Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Income from Continuing Operations amounts to 691.4m CNY.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
27%

Over the last year, the Income from Continuing Operations growth was 144%.

Back to Top